Showing results (51-60 of 117) with videos related to
Sort By:
Pageof 12
Journal of Neurology|November 20, 2023
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Federica Matrone, Marco Capobianco, et al.Multiple Sclerosis and Related Disorders|May 10, 2023
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosisGianmarco Abbadessa, Marta Ponzano, Floriana Bile, et al.Nutrients|July 30, 2017
Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 PatientsTeresa Esposito, Carla Schettino, Paola Polverino, et al.Journal of Neurology|May 4, 2024
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched studyAurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 24, 2026
The perception of disability in multiple sclerosis: validation and psychometric properties of the Italian perceived disability scaleGina Ferrazzano, Simona Raimo, Antonella Di Vita, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 17, 2022
Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspectiveGiacomo Lus, Marco André Bassano, Vincenzo Brescia Morra, et al.Journal of Clinical Medicine|March 11, 2023
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World EvidenceElisabetta Signoriello, Giacomo Lus, Francesco Saccà, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 11, 2022
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With OcrelizumabDoriana Landi, Alfonso Grimaldi, Francesca Bovis, et al.Journal of Alzheimer'S Disease : JAD|October 5, 2020
The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman EmpireCinzia Coppola, Dario Saracino, Mariano Oliva, et al.Pageof 12